- Home
- CMRX vs CNTB Comparison
CMRX vs CNTB Comparison
Compare CMRX & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRX
- CNTB
- Stock Information
- Founded
- CMRX 2000
- CNTB 2012
- Country
- CMRX United States
- CNTB United States
- Employees
- CMRX N/A
- CNTB N/A
- Industry
- CMRX Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- CMRX Health Care
- CNTB Health Care
- Exchange
- CMRX Nasdaq
- CNTB Nasdaq
- Market Cap
- CMRX 77.1M
- CNTB 65.5M
- IPO Year
- CMRX 2013
- CNTB 2021
- Fundamental
- Price
- CMRX $0.86
- CNTB $1.11
- Analyst Decision
- CMRX Strong Buy
- CNTB Strong Buy
- Analyst Count
- CMRX 1
- CNTB 1
- Target Price
- CMRX $11.00
- CNTB $8.00
- AVG Volume (30 Days)
- CMRX 282.9K
- CNTB 28.8K
- Earning Date
- CMRX 11-07-2024
- CNTB 09-05-2024
- Dividend Yield
- CMRX N/A
- CNTB N/A
- EPS Growth
- CMRX N/A
- CNTB N/A
- EPS
- CMRX N/A
- CNTB N/A
- Revenue
- CMRX $159,000.00
- CNTB $24,116,000.00
- Revenue This Year
- CMRX $1,772.84
- CNTB N/A
- Revenue Next Year
- CMRX N/A
- CNTB $63.90
- P/E Ratio
- CMRX N/A
- CNTB N/A
- Revenue Growth
- CMRX N/A
- CNTB N/A
- 52 Week Low
- CMRX $0.75
- CNTB $0.68
- 52 Week High
- CMRX $1.30
- CNTB $2.84
- Technical
- Relative Strength Index (RSI)
- CMRX 41.07
- CNTB 45.31
- Support Level
- CMRX $0.91
- CNTB $0.98
- Resistance Level
- CMRX $1.12
- CNTB $1.09
- Average True Range (ATR)
- CMRX 0.09
- CNTB 0.10
- MACD
- CMRX -0.01
- CNTB -0.01
- Stochastic Oscillator
- CMRX 10.31
- CNTB 31.28
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.